Volume 11, Number 8—August 2005
Research
Influenza A (H3N2) Outbreak, Nepal
Table 2
Virus strain | Amino acid position |
|||||
---|---|---|---|---|---|---|
145 Glycosylation site adjacent to antibody site A | 155 Fujian-like lineage amino acid substitution | 156 Fujian-like lineage amino acid substitution | 189 Antibody site B | 226 Antibody site D | 227 Antibody site D | |
A/Nepal Consensus/04† | N | T | H | N | I | P |
A/Fujian/411/02 | K | T | H | S | V | S |
A/Wyoming/3/03 | K | T | H | S | I | S |
A/Wellington/1/04 | K | T | H | N | V | P |
A/California/7/04 | N | T | H | N | I | P |
A/Panama/2007/99 | K | H | Q | S | V | S |
*N, asparagine; T, threonine; H, histidine; I, isoleucine; P, proline; K, lysine; S, serine; V, valine; Q, glutamine.
†Consensus sequence derived from a multiple sequence protein alignment of 26 HA1 hemagglutinin sequences from Nepal.
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.